Search Results

You are looking at 41 - 50 of 899 items for :

  • "metastases" x
  • Refine by Access: All x
Clear All
Full access

HSR24-154: Real-World Clinical Outcomes in Patients With Advanced/Metastatic Melanoma and Brain Metastases Treated With Pembrolizumab Monotherapy—An Analysis of the ADOReg German Skin Cancer Registry

Ruixuan Jiang, Michael Weichenthal, Cesar I. Fernandez-Lazaro, Anja Rudolph, Clemens Krepler, Peter Mohr, and on behalf of the ADOReg investigators

Background: Brain metastases are associated with poor clinical outcomes in advanced/metastatic melanoma, with median overall survival (OS), historically, of 3–6 months. The ADOReg German skin cancer registry provides an opportunity to evaluate

Full access

PTCH1-GLI1 Fusion–Positive Ovarian Tumor: Report of a Unique Case With Response to Tyrosine Kinase Inhibitor Pazopanib

Rofieda R. Alwaqfi, Megan I. Samuelson, Natalya N. Guseva, Michelle Ouyang, Aaron D. Bossler, and Deqin Ma

pelvis and involving both adnexa (circle). ( B ) Preoperative axial CT images of the upper abdomen show peritoneal carcinomatosis (arrow). ( C ) Coronal CT images show recurrence of disease with multiple hepatic metastases (arrows) and bilateral

Full access

TIP24-199: Rhenium (Re-186) Obisbemeda {Re-186-Nanoliposome (186RNL)} in Leptomeningeal Metastases [LM] Phase 1/2A Dose Escalation Trial: Update of Initial Safety and Feasibility Through Cohorts 1–4

Norman LaFrance, Andrew Brenner, Priya Kumthekar, Michael Youssef, Ande Bao, Melissa Moore, Joel Michalek, Marc Hedrick, William Phillips, Toral Patel, Jeffrey Weinberg, and John Floyd

Background: Leptomeningeal metastases (LM) are devastating systemic cancer complications commonly seen with breast, lung, renal cell, and melanoma, with limited treatment options and poor survival. Re-186–obisbemeda provides the combination of

Full access

Sentinel Lymph Node Mapping for Endometrial Cancer: A Modern Approach to Surgical Staging

Nadeem R. Abu-Rustum

Incidence of Ultrastage-Detected, Low-Volume Metastases in Sentinel Lymph Nodes According to Final Histologic Grade and Depth of Myometrial Invasion Table 3 Performance of SLN Mapping Alone Compared With the Algorithm for All Patients

Full access

CLO22-074: Patient-Reported Outcomes (PROs) in Patients (pts) With Advanced Non-Small Cell Lung Cancer (aNSCLC) With Programmed Cell Death-Ligand 1 (PD-L1) ≥50% Receiving Cemiplimab (CEMI) Monotherapy Versus Platinum-Doublet Chemotherapy (CHEMO): A Focus on the EMPOWER-Lung 1 Brain Metastases Subpopulation

Mustafa Özgüroğlu, Ahmet Sezer, Saadettin Kilickap, Mahmut Gümüş, Igor Bondarenko, Miranda Gogishvili, Xuanyao He, Jennifer McGinniss, Giuseppe Gullo, Petra Rietschel, and Ruben GW Quek

≥50% and clinically stable treated brain metastases at baseline. Post-hoc exploratory analyses were conducted to evaluate PROs in this subgroup of pts. Methods : PROs were assessed at baseline and day 1 of each treatment cycle for the first 6 cycles

Full access

Guidelines for the Initial Management of Metastatic Brain Tumors: Role of Surgery, Radiosurgery, and Radiation Therapy

Matthew G. Ewend, David E. Morris, Lisa A. Carey, Alim M. Ladha, and Steven Brem

metastases. Histology, multiplicity, surgery, and survival . Cancer 1996 ; 78 : 1781 – 1788 . 2. Patchell RA Tibbs PA Regine WF . Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial . JAMA 1998

Full access

Role of Prophylactic Cranial Irradiation in Extensive-Stage Small Cell Lung Cancer

Nathan Y. Yu, Terence T. Sio, Vinicius Ernani, Panayiotis Savvides, and Steven E. Schild

SCLC has one of the highest propensities to spread to the brain. 1 With as many as three-quarters of patients developing brain metastases during their disease course, reducing the risk of central nervous system (CNS) failure appears important. 2

Full access

Counterpoint: Sentinel Lymph Node Biopsy Is Not Indicated for Ductal Carcinoma In Situ

Stephen B. Edge and David G. Sheldon

. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures . Cancer 1982 ; 50 : 1309 – 1314 . 17 Silverstein MJ Lagios MD Martino S . Outcome after

Full access

Major Response to Cyclophosphamide and Prednisone in Recurrent Castration-Resistant Prostate Cancer

Nicolas Batty, Naveen Yarlagadda, and Roberto Pili

metastases and an irregular tumor protruding into the bladder lumen with bilateral pelvic lymphadenopathy. ADT was initiated with leuprolide, 30 mg, subcutaneously, and bicalutamide, 50 mg, orally daily. A biochemical response occurred, with a nadir PSA of 6

Full access

Complete Response to Erlotinib and Bevacizumab in a Patient With Biphenotypic (Hepatobiliary) Primary Liver Carcinoma

Amy Zhou, Manik Amin, Kathryn J. Fowler, Elizabeth M. Brunt, Jesse Keller, and Benjamin Tan

revealed recurrent diffuse omental metastases. She was then restarted on erlotinib and bevacizumab, with prompt resolution of her ascites and abdominal discomfort. Bevacizumab was subsequently held a month after retreatment because of hypertension and chest